300 related articles for article (PubMed ID: 15215130)
1. Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonization.
Shah A; Mond J; Walsh S
Antimicrob Agents Chemother; 2004 Jul; 48(7):2704-7. PubMed ID: 15215130
[TBL] [Abstract][Full Text] [Related]
2. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice.
Kokai-Kun JF; Chanturiya T; Mond JJ
J Antimicrob Chemother; 2009 Jul; 64(1):94-100. PubMed ID: 19398455
[TBL] [Abstract][Full Text] [Related]
3. Lysostaphin: an antistaphylococcal agent.
Kumar JK
Appl Microbiol Biotechnol; 2008 Sep; 80(4):555-61. PubMed ID: 18607587
[TBL] [Abstract][Full Text] [Related]
4. Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication.
Walencka E; Sadowska B; Rozalska S; Hryniewicz W; Rózalska B
Pol J Microbiol; 2005; 54(3):191-200. PubMed ID: 16450834
[TBL] [Abstract][Full Text] [Related]
5. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin.
Graham S; Coote PJ
J Antimicrob Chemother; 2007 Apr; 59(4):759-62. PubMed ID: 17324959
[TBL] [Abstract][Full Text] [Related]
6. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces.
Wu JA; Kusuma C; Mond JJ; Kokai-Kun JF
Antimicrob Agents Chemother; 2003 Nov; 47(11):3407-14. PubMed ID: 14576095
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus.
LaPlante KL
Diagn Microbiol Infect Dis; 2007 Apr; 57(4):413-8. PubMed ID: 17141452
[TBL] [Abstract][Full Text] [Related]
8. Antagonistic activities of coagulase-positive staphylococci.
Balusek J; Hájek V
J Hyg Epidemiol Microbiol Immunol; 1985; 29(2):147-54. PubMed ID: 4020118
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci.
Lee JY; Ko KS; Peck KR; Oh WS; Song JH
J Antimicrob Chemother; 2006 Jun; 57(6):1110-5. PubMed ID: 16556639
[TBL] [Abstract][Full Text] [Related]
10. Surface disinfection properties of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, against methicillin-resistant Staphylococcus aureus (MRSA).
Desbois AP; Lang S; Gemmell CG; Coote PJ
J Appl Microbiol; 2010 Feb; 108(2):723-30. PubMed ID: 19709343
[TBL] [Abstract][Full Text] [Related]
11. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
Becker SC; Foster-Frey J; Donovan DM
FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148
[TBL] [Abstract][Full Text] [Related]
12. Linezolid resistance in coagulase-negative staphylococci.
Kelly S; Collins J; Davin M; Gowing C; Murphy PG
J Antimicrob Chemother; 2006 Oct; 58(4):898-9; author reply 899-900. PubMed ID: 16854956
[No Abstract] [Full Text] [Related]
13. [Studies with lysostaphin. I. Lysostaphin sensitivity of 355 strains of Staph. aureus of human origin].
Pulverer G
Z Med Mikrobiol Immunol; 1968; 154(1):40-8. PubMed ID: 5710870
[No Abstract] [Full Text] [Related]
14. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model.
Kokai-Kun JF; Chanturiya T; Mond JJ
J Antimicrob Chemother; 2007 Nov; 60(5):1051-9. PubMed ID: 17848374
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China.
Yang XY; Li CR; Lou RH; Wang YM; Zhang WX; Chen HZ; Huang QS; Han YX; Jiang JD; You XF
J Med Microbiol; 2007 Jan; 56(Pt 1):71-76. PubMed ID: 17172520
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.
Karlowsky JA; Laing NM; Baudry T; Kaplan N; Vaughan D; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2007 Apr; 51(4):1580-1. PubMed ID: 17220418
[No Abstract] [Full Text] [Related]
17. [Are we being threatened by multiresistant strains of Staphylococcus aureus?].
Aepfelbacher M
MMW Fortschr Med; 2005 Jan; 147(4):33-5, 37. PubMed ID: 15745339
[TBL] [Abstract][Full Text] [Related]
18. Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis.
Kiri N; Archer G; Climo MW
Antimicrob Agents Chemother; 2002 Jun; 46(6):2017-20. PubMed ID: 12019130
[TBL] [Abstract][Full Text] [Related]
19. [Staphylococcus aureus-lysing enzymes: isolation and some properties of lysostaphine].
Surovtsev VI; Gusev VV; Borozdina MA; Paderin IuP; Khatiushin IuI; Chuprunov VP
Vestn Ross Akad Med Nauk; 1999; (12):22-4. PubMed ID: 10709462
[TBL] [Abstract][Full Text] [Related]
20. Telavancin: in vitro activity against staphylococci in a biofilm model.
Gander S; Kinnaird A; Finch R
J Antimicrob Chemother; 2005 Aug; 56(2):337-43. PubMed ID: 15972312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
